CRDF רווח למניה בשנים עשר החודשים האחרונים Cardiff Oncology Corp

Cardiff Oncology, Inc. (CRDF) is expanding its presence in the tumor resistance segment by implementing a precision therapy ecosystem based on Onvansertib and PLK1 to create exclusive protocols. The annual EPS TTM snapshot demonstrates profit dynamics, with the metric holding around -0.54. The asset's value is based on scientific potential in the field of vital oncology, which renders the business a defensive asset against GDP fluctuations.
Cardiff Oncology, Inc. - פילוחים אנליטיים ומדדי מפתח (CRDF)

Earnings per share (EPS TTM) reflects the portion of annual net income allocated to each security, allowing for an assessment of the business's actual capitalization efficiency regardless of the total issuance volume. By analyzing the trailing specific earnings of Cardiff Oncology, Inc. (CRDF), an investor can see how support from pharma behemoths and the success of oncology drugs translate into the asset's financial stability.